" class="no-js "lang="en-US"> ViroCell Announces the Appointment of Susan B. Nichols as CBO - Medtech Alert
Sunday, April 14, 2024

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies. The appointment of Susan as CBO is a significant milestone in ViroCell’s continuing operational development as a future leader in the clinical trial CDMO market and her appointment brings with it, Susan’s passion to assist clients in accelerating their innovative product candidates into and through clinical trials.

Susan has a distinguished track record as an executive and business development professional and currently sits on the Board of Directors of the Alliance for Regenerative Medicine (“ARM”), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.  Susan is also Co-Chair of its Accelerator Committee and Co-Chair of ARM’s Womens’ Executive Forum.

Most recently, Susan was an executive officer at Propel BioSciences, Cary N.C. as part of the Entrepreneurial Consulting Team, supporting the business development and funding needs of early-stage biotech and pharmaceutical companies.  Prior to that, Susan was Chief Executive Officer (“CEO”) of Falcon Therapeutics, Durham N.C., an early-stage gene modified cell therapy company focused on solid tumors.  Susan joined Falcon in 2018 to apply her manufacturing, operational and fundraising experience to take a promising academic candidate to clinical trial readiness.

John W Hadden II, CEO at ViroCell, commented:
“This is a very exciting time for ViroCell as we continue to scale the organization to meet the explosive demand from clients for viral vectors for clinical trials. We are thrilled that Susan has joined our rapidly expanding senior leadership team. Her proven track record in leading external business development will help ViroCell to achieve market leading status in the near term. We look forward to Susan’s unique insights and contributions to ViroCell’s success.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more